Hypoxia and metabolism: Hypoxia, DNA repair and genetic instability

Nature Reviews Cancer

Volumn 8, Issue 3, 2008, Pages 180-192

  Bristow, Robert G ^a   Hill, Richard P ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLE STRANDED DNA;

CELL SURVIVAL; CHEMOSENSITIVITY; CHROMATIN; DNA REPAIR; GENETIC TRANSCRIPTION; GENOMIC INSTABILITY; HUMAN; HYPOXIA; METASTASIS; MUTATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RADIOSENSITIVITY; REVIEW; RNA TRANSLATION; TUMOR GROWTH;

ANIMALS; ANOXIA; DISEASE PROGRESSION; DNA DAMAGE; DNA REPAIR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC INSTABILITY; HUMANS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASMS; PHENOTYPE; PROTEIN BIOSYNTHESIS; TRANSCRIPTION, GENETIC;

EID: 39749114978     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2344     Document Type: Review

References (110)

1. Blais, J. D. et al. Perk-dependent translational regulation promotes tumor cell adaptation and angiogenesis in response to hypoxic stress. Mol. Cell Biol. 26, 9517-9532 (2006).
2. Tatum, J. L. et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int. J. Radiat. Biol. 82, 699-757 (2006).
3. Brizel, D. M. et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 56, 941-943 (1996).
4. Chan, N., Milosevic, M. & Bristow, R. G. Tumor hypoxia, DNA repair and prostate cancer progression: new targets and new therapies. Future Oncol. 3, 329-341 (2007).
5. Chaudary, N. & Hill, R. P. Hypoxia and metastasis. Clin. Cancer Res. 13, 1947-1949 (2007).
6. Vaupel, P. & Mayer, A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 26, 225-239 (2007). An excellent review of the role that hypoxia has in determining local control following therapy and metastatic spread.
7. 2 homeostasis by hypoxia-inducible factor 1. Annu. Rev. Cell Dev. Biol. 15, 551-578 (1999).
8. Salceda, S. & Caro, J. Hypoxia-inducible factor 1α (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J. Biol. Chem. 272, 22642-22647 (1997).
9. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl Acad. Sci. USA 95, 7987-7992 (1998).
10. Semenza, G. L. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov. Today 12, 853-859 (2007).
11. Giaccia, A., Siim, B. G. & Johnson, R. S. HIF-1 as a target for drug development. Nature Rev. Drug Discov. 2, 803-811 (2003).
12. Moeller, B. J., Richardson, R. A. & Dewhirst, M. W. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev. 26, 241-248 (2007).
13. Harris, A. L. Hypoxia - a key regulatory factor in tumour growth. Nature Rev. Cancer 2, 38-47 (2002).
14. Petersen, I. Antiangiogenesis, anti-VEGF(R) and outlook. Recent Results Cancer Res. 176, 189-199 (2007).
15. Chi, J. T. et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med. 3, e47 (2006).
16. Koritzinsky, M. et al. The hypoxic proteome is influenced by gene-specific changes in mRNA translation. Radiother Oncol. 76, 177-186 (2005).
17. Wouters, B. G. et al. Control of the hypoxic response through regulation of mRNA translation. Semin. Cell Dev. Biol. 16, 487-501 (2005).
18. Koritzinsky, M. et al. Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control. EMBO J. 25, 1114-1125 (2006). Recent work delineating distinct pathways that regulate translation in response to hypoxia, thereby giving rise to differential gene expression.
19. Koritzinsky, M. et al. Phosphorylation of eIF2α is required for mRNA translation inhibition and survival during moderate hypoxia. Radiother. Oncol. 83, 353-361 (2007).
20. Papandreou, I. et al. Anoxia is necessary for tumor cell toxicity caused by a low-oxygen environment. Cancer Res. 65, 3171-3178 (2005).
21. Bindra, R. S., Crosby, M. E. & Glazer, P. M. Regulation of DNA repair in hypoxic cancer cells. Cancer Metastasis Rev. 26, 249-260 (2007).
22. Huang, L. E., Bindra, R. S., Glazer, P. M. & Harris, A. L. Hypoxia-induced genetic instability - a calculated mechanism underlying tumor progression. J. Mol. Med. 85, 139-148 (2007).
23. Rofstad, E. K., Galappathi, K., Mathiesen, B. & Ruud, E. B. Fluctuating and diffusion-limited hypoxia in hypoxia-induced metastasis. Clin. Cancer Res. 13, 1971-1978 (2007).
24. Hill, R. & Bristow, R. G. in The Basic Science of Oncology 4th edn (eds Tannock, I. F., Hill, R. P., Harrington, L. & Bristow, R.G.) 289-321 (McGraw-Hill, New York, 2005).
25. Olive, P. L. & Banath, J. P. Phosphorylation of histone H2AX as a measure of radiosensitivity. Int. J. Radiat. Oncol. Biol. Phys. 58, 331-335 (2004).
26. Frankenberg-Schwager, M., Frankenberg, D. & Harbich, R. Different oxygen enhancement ratios for induced and unrejoined DNA double-strand breaks in eukaryotic cells. Radiat. Res. 128, 243-250 (1991).
27. Terris, D. J. et al. Estimating DNA repair by sequential evaluation of head and neck tumor radiation sensitivity using the comet assay. Arch. Otolaryngol. Head Neck Surg. 128, 698-702 (2002).
28. Wang, J., Biedermann, K. A. & Brown, J. M. Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res. 52, 4473-4477 (1992).
29. Brown, J. M., Evans, J. & Kovacs, M. S. The prediction of human tumor radiosensitivity in situ: an approach using chromosome aberrations detected by fluorescence in situ hybridization. Int. J. Radiat. Oncol. Biol. Phys. 24, 279-286 (1992).
30. Zhang, H., Koch, C. J., Wallen, C. A. & Wheeler, K. T. Radiation-induced DNA damage in tumors and normal tissues. III. Oxygen dependence of the formation of strand breaks and DNA-protein crosslinks. Radiat. Res. 142, 163-168 (1995).
31. Wardman, P. Chemical radiosensitizers for use in radiotherapy. Clin. Oncol. (R. Coll. Radiol) 19, 397-417 (2007).
32. Overgaard, J. Hypoxic radiosensitization: adored and ignored. J. Clin. Oncol. 25, 4066-4074 (2007). An important review of the history of the study of hypoxia in terms of predicting response to radiotherapy and radiosensitization strategies based on targeting hypoxic cells.
33. Shannon, A. M., Bouchier-Hayes, D. J., Condron, C. M. & Toomey, D. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat. Rev. 29, 297-307 (2003).
34. Minchinton, A. I. & Tannock, I. F. Drug penetration in solid tumours. Nature Rev. Cancer 6, 583-592 (2006).
35. Moeller, B. J. et al. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8, 99-110 (2005). This paper reported that fractionated radiotherapy could increase HIF1 with consequential effects on tumour cells and tumour endothelium.
36. Unruh, A. et al. The hypoxia-inducible factor-1 α is a negative factor for tumor therapy. Oncogene 22, 3213-3220 (2003).
37. Martinive, P. et al. Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies. Cancer Res. 66, 11736-11744 (2006).
38. Koritzinsky, M., Wouters, B. G., Amellem, O. & Pettersen, E. O. Cell cycle progression and radiation survival following prolonged hypoxia and reoxygenation. Int. J. Radiat. Biol. 77, 319-328 (2001).
39. Zolzer, F. & Streffer, C. Increased radiosensitivity with chronic hypoxia in four human tumor cell lines. Int. J. Radiat. Oncol. Biol. Phys. 54, 910-920 (2002).
40. Shrieve, D. C. & Harris, J. W. The in vitro sensitivity of chronically hypoxic EMT6/SF cells to X-radiation and hypoxic cell radiosensitizers. Int. J. Radiat. Biol. Relat Stud Phys. Chem. Med. 48, 127-138 (1985). One of the first reports suggesting that cells that are exposed to chronic hypoxia may have a different OER to cells that are exposed to acute hypoxia
41. Hockel, M. et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56, 4509-4515 (1996).
42. Young, S. D., Marshall, R. S. & Hill, R. P. Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc. Natl Acad. Sci. USA 85, 9533-9537 (1988). One of the first important papers to link genetic instability, chemosensitivity and mestastasis to hypoxia
43. Young, S. D. & Hill, R. P. Effects of reoxygenation on cells from hypoxic regions of solid tumors: anticancer drug sensitivity and metastatic potential. J. Natl Cancer Inst. 82, 371-380 (1990). Another of the first important papers to link genetic instability, chemosensitivity and mestastasis to hypoxia
44. Cairns, R. A. & Hill, R. P. Acute hypoxia enhances spontaneous lymph node metastasis in an orthotopic murine model of human cervical carcinoma. Cancer Res. 64, 2054-2061 (2004).
45. Papp-Szabo, E., Josephy, P. D. & Coomber, B. L. Microenvironmental influences on mutagenesis in mammary epithelial cells. Int. J. Cancer 116, 679-685 (2005).
46. Luk, C. K., Veinot-Drebot, L., Tjan, E. & Tannock, I. F. Effect of transient hypoxia on sensitivity to doxorubicin in human and murine cell lines. J. Natl Cancer Inst. 82, 684-692 (1990).
47. Rofstad, E. K. Microenvironment-induced cancer metastasis. Int. J. Radiat. Biol. 76, 589-605 (2000).
48. Erler, J. T. et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440, 1222-1226 (2006).
49. Chan, D. A. & Giaccia, A. J. Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev. 26, 333-339 (2007).
50. Kaplan, R. N., Rafii, S. & Lyden, D. Preparing the "soil": the premetastatic niche. Cancer Res. 66, 11089-11093 (2006).
51. Graeber, T. G. et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379, 88-91 (1996).
52. Zhang, L. & Hill, R. P. Hypoxia enhances metastatic efficiency by up-regulating Mdm2 in KHT cells and increasing resistance to apoptosis. Cancer Res. 64, 4180-4189 (2004).
53. Zhang, L. & Hill, R. P. Hypoxia enhances metastatic efficiency in HT1080 fibrosarcoma cells by increasing cell survival in lungs, not cell adhesion and invasion. Cancer Res. 67, 7789-7797 (2007).
54. Graeber, T. G. et al. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol. Cell Biol. 14, 6264-6277 (1994).
55. Nordsmark, M. et al. Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br. J. Cancer 84, 1070-1075 (2001).
56. Cairns, R. A., Kalliomaki, T. & Hill, R. P. Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors. Cancer Res. 61, 8903-8908 (2001).
57. Kim, J. W., Gao, P. & Dang, C. V. Effects of hypoxia on tumor metabolism. Cancer Metastasis Rev. 26, 291-298 (2007).
58. Bell, E. L. & Chandel, N. S. Mitochondrial oxygen sensing: regulation of hypoxia-inducible factor by mitochondrial generated reactive oxygen species. Essays Biochem. 43, 17-27 (2007).
59. Guzy, R. D. & Schumacker, P. T. Oxygen sensing by mitochondria at complex III: the paradox of increased reactive oxygen species during hypoxia. Exp. Physiol. 91, 807-819 (2006).
60. Gibson, S. L., Bindra, R. S. & Glazer, P. M. Hypoxia-induced phosphorylation of Chk2 in an ataxia telangiectasia mutated-dependent manner. Cancer Res. 65, 10734-10741 (2005).
61. 2 leads to an ATM-dependent checkpoint and that reoxygenation leads to a CHK2-dependent checkpoint.
62. Hammond, E. M., Dorie, M. J. & Giaccia, A. J. ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation. J. Biol. Chem. 278, 12207-12213 (2003).
63. Hammer, S., To, K. K., Yoo, Y. G., Koshiji, M. & Huang, L. E. Hypoxic suppression of the cell cycle gene CDC25A in tumor cells. Cell Cycle 6, 1919-1926 (2007).
64. Reynolds, T. Y., Rockwell, S. & Glazer, P. M. Genetic instability induced by the tumor microenvironment. Cancer Res. 56, 5754-5757 (1996). A first paper supporting the concept that hypoxic cells have increased mutation rates.
65. Li, C. Y. et al. Persistent genetic instability in cancer cells induced by non-DNA-damaging stress exposures. Cancer Res. 61, 428-432 (2001).
66. Sandhu, J. K., Haqqani, A. S. & Birnboim, H. C. Effect of dietary vitamin E on spontaneous or nitric oxide donor-induced mutations in a mouse tumor model. J. Natl Cancer Inst. 92, 1429-1433 (2000).
67. Banath, J. P., Sinnott, L., Larrivee, B., MacPhail, S. H. & Olive, P. L. Growth of V79 cells as xenograft tumors promotes multicellular resistance but does not increase spontaneous or radiation-induced mutant frequency. Radiat. Res. 164, 733-744 (2005).
68. Weterings, E. & van Gent, D. C. The mechanism of non-homologous end-joining: a synopsis of synapsis. DNA Repair (Amst.) 3, 1425-1435 (2004).
69. van Gent, D. C., Hoeijmakers, J. H. & Kanaar, R. Chromosomal stability and the DNA double-stranded break connection. Nature Rev. Genet. 2, 196-206 (2001).
70. Helleday, T., Lo, J., van Gent, D. C. & Engelward, B. P. DNA double-strand break repair: from mechanistic understanding to cancer treatment. DNA Repair (Amst.) 6, 923-935 (2007).
71. Collis, S. J., DeWeese, T. L., Jeggo, P. A. & Parker, A. R. The life and death of DNA-PK. Oncogene 24, 949-961 (2005).
72. Raderschall, E. et al. Elevated levels of Rad51 recombination protein in tumor cells. Cancer Res. 62, 219-225 (2002).
73. Bertrand, P., Lambert, S., Joubert, C. & Lopez, B. S. Overexpression of mammalian Rad51 does not stimulate tumorigenesis while a dominant-negative Rad51 affects centrosome fragmentation, ploidy and stimulates tumorigenesis, in p53-defective CHO cells. Oncogene 22, 7587-7592 (2003).
74. Stark, J. M., Pierce, A. J., Oh, J., Pastink, A. & Jasin, M. Genetic steps of mammalian homologous repair with distinct mutagenic consequences. Mol. Cell Biol. 24, 9305-9316 (2004).
75. Ouyang, H. et al. Ku70 is required for DNA repair but not for T cell antigen receptor gene recombination in vivo. J. Exp. Med. 186, 921-929 (1997).
76. Powell, S. N. & Kachnic, L. A. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene 22, 5784-5791 (2003).
77. Chan, N. M. A. et al. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res. 68, 605-614 (2008). An important paper that shows differential HR and sensitivity to radiotherapy and chemotherapy in cells exposed to acute versus chronic hypoxia
78. Bindra, R. S. & Glazer, P. M. Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia. Oncogene 26, 2048-2057 (2007).
79. Sprong, D., Janssen, H. L., Vens, C. & Begg, A. C. Resistance of hypoxic cells to ionizing radiation is influenced by homologous recombination status. Int. J. Radiat. Oncol. Biol. Phys. 64, 562-572 (2006).
80. Murray, D., Macann, A., Hanson, J. & Rosenberg, E. ERCC1/ERCC4 5′-endonuclease activity as a determinant of hypoxic cell radiosensitivity. Int. J. Radiat. Biol. 69, 319-327 (1996).
81. Murray, D., Vallee-Lucic, L., Rosenberg, E. & Andersson, B. Sensitivity of nucleotide excision repair-deficient human cells to ionizing radiation and cyclophosphamide. Anticancer Res. 22, 21-26 (2002).
82. Bindra, R. S. et al. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol. Cell Biol. 24, 8504-8518 (2004). The first paper to document decreased RAD51 expression as a function of hypoxia in tissue culture and xenograft models.
83. Meng, A. X. et al. Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiother Oncol. 76, 168-176 (2005).
84. Bindra, R. S. & Glazer, P. M. Genetic instability and the tumor microenvironment: towards the concept of microenvironment-induced mutagenesis. Mutat. Res. 569, 75-85 (2005).
85. Um, J. H. et al. Association of DNA-dependent protein kinase with hypoxia inducible factor-1 and its implication in resistance to anticancer drugs in hypoxic tumor cells. Exp. Mol. Med. 36, 233-242 (2004).
86. To, K. K., Sedelnikova, O. A., Samons, M., Bonner, W. M. & Huang, L. E. The phosphorylation status of PAS-B distinguishes HIF-1α from HIF-2α in NBS1 repression. EMBO J. 25, 4784-4794 (2006).
87. Mihaylova, V. T. et al. Decreased expression of the DNA mismatch repair gene Mlh1 under hypoxic stress in mammalian cells. Mol. Cell Biol. 23, 3265-3273 (2003).
88. Koshiji, M. et al. HIF-1α induces genetic instability by transcriptionally downregulating MutSα expression. Mol. Cell 17, 793-803 (2005). References 87 and 88 were the first papers to document decreased MMR protein expression in hypoxic cells.
89. Bindra, R. S. & Glazer, P. M. Co-repression of mismatch repair gene expression by hypoxia in cancer cells: role of the Myc/Max network. Cancer Lett. 252, 93-103 (2007).
90. Gordan, J. D., Bertout, J. A., Hu, C. J., Diehl, J. A. & Simon, M. C. HIF-2α promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 11, 335-347 (2007).
91. Huang, L. E. Carrot and stick: HIF-α engages c-Myc in hypoxic adaptation. Cell Death Differ. 11 Jan 2008 (doi: 10.1038/sj.cdd.4402302).
92. Liu, L. et al. Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol. Cell 21, 521-531 (2006).
93. Zhu, Y., McAvoy, S., Kuhn, R. & Smith, D. I. RORA, a large common fragile site gene, is involved in cellular stress response. Oncogene 25, 2901-2908 (2006).
94. Coquelle, A., Pipiras, E., Toledo, F., Buttin, G. & Debatisse, M. Expression of fragile sites triggers intrachromosomal mammalian gene amplification and sets boundaries to early amplicons. Cell 89, 215-225 (1997).
95. Coquelle, A., Toledo, F., Stern, S., Bieth, A. & Debatisse, M. A new role for hypoxia in tumor progression: induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs. Mol. Cell 2, 259-265 (1998). References 94 and 95 are important papers linking hypoxia to genetic instability through increased chromosomal rearrangement, gene amplification and induction of intrachromosomal fragile sites
96. Yatabe, N. et al. HIF-1-mediated activation of telomerase in cervical cancer cells. Oncogene 23, 3708-3715 (2004).
97. Anderson, C. J., Hoare, S. F., Ashcroft, M., Bilsland, A. E. & Keith, W. N. Hypoxic regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms. Oncogene 25, 61-69 (2006).
98. Pandey, R., Heeger, S. & Lehner, C. F. Rapid effects of acute anoxia on spindle kinetochore interactions activate the mitotic spindle checkpoint. J. Cell Sci. 120, 2807-2818 (2007).
99. Johnson, A. B. & Barton, M. C. Hypoxia-induced and stress-specific changes in chromatin structure and function. Mutat. Res. 618, 149-162 (2007).
100. Klein, E. A., Casey, G. & Silverman, R. Genetic susceptibility and oxidative stress in prostate cancer: integrated model with implications for prevention. Urology 68, 1145-1151 (2006).
101. Gao, P. et al. HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 12, 230-238 (2007). Provocative paper showing that antioxidants may prevent cancer progression through inhibition of HIF1-mediated angiogenesis rather than inhibition of genetic instability.
102. Bristow, R. & Hill, R. in The Basic Science of Oncology 4th edn (eds Tannock, I., Hill, R. P, Harrington, L. & Bristow, R.) 261-288 (McGraw-Hill, New York, 2005).
103. Brown, J. M. & Wilson, W. R. Exploiting tumour hypoxia in cancer treatment. Nature Rev. Cancer 4, 437-447 (2004).
104. Evans, J. W. et al. Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells. Cancer Res. 68, 257-265 (2008).
105. Choudhury, A., Cuddihy, A. & Bristow, R. G. Radiation and new molecular agents part I: targeting ATM-ATR checkpoints, DNA repair, and the proteasome. Semin. Radiat. Oncol. 16, 51-58 (2006).
106. Soldatenkov, V. A. & Potaman, V. N. DNA-binding properties of poly(ADP-ribose) polymerase: a target for anticancer therapy. Curr. Drug Targets. 5, 357-365 (2004).
107. Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917 (2005).
108. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005).
109. McCabe, N. et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66, 8109-8115 (2006). References 107, 108 and 109 showed that synthetic lethality occurred in HR-defective cells that were treated with PARP inhibitors in tumour cell models.
110. Kennedy, R. D. et al. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J. Clin. Invest. 117, 1440-1449 (2007).